LuisE.FayadMD

Oncology • Houston, TX

Associate Professor of Medicine, University Tex Houston

Join to view full profile

Dr. Fayad is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Fayad's full profile

Already have an account?

Office
1515 Holcombe Blvd
Unit 429
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1994 - 1997
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1993 - 1994
University of Miami/Jackson Health SystemResidency, Internal Medicine, 1990 - 1993
Universidad Catolica de Santiago de GuayaquilClass of 1985

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 1995 - 2026
OK State Medical License 2020 - 2021
AZ State Medical License 1999 - 2014
NV State Medical License 1997 - 2011

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy Start of enrollment: 2002 May 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Start of enrollment: 2002 Feb 01
Unknown status
Phase 1
Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger Start of enrollment: 2005 Aug 01
Completed
Phase 2
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2006 Sep 01
Terminated
Phase 2
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) Start of enrollment: 2013 Aug 01
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type: A Role for Elective Nodal Irradiation?
Penny Fang, Sonal S Noticewala, Susan Y Wu, Jillian R Gunther, Ethan B Ludmir
Advances in Radiation Oncology. 2024-12-01
Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy.
Rishika Prasad, Abdur Rehman, Lubna Rehman, Faezeh Darbaniyan, Viktoria Blumenberg
Blood. 2024-10-23
Characterization of Lymphopenia and Correlating the Risk of Cytopenias With Dose and Bone Marrow Volume Irradiated in Aggressive B Cell Lymphoma Patients Bridged With ...
Gohar S Manzar, Susan Y Wu, Stephanie O Dudzinski, Elaine E Cha, Alison K Yoder
International Journal of Radiation Oncology, Biology, Physics. 2024-09-19

Journal Articles

Long‐Term Overall‐ and Progression‐Free Survival After Pentostatin, Cyclophosphamide and Rituximab Therapy for Indolent Non‐Hodgkin Lymphoma
Peter McLaughlin, M Alma Rodriguez, Sattva S Neelapu, Anas Younes, Lei Feng, Michelle A Fanale, Felipe Samaniego, Barbara Pro, Luis Fayad, Fredrick Hagemeister, Jorge ..., British Journal of Haematology
Rituximab with ABVD vs ABVD for Advanced Stage High-Risk Classical Hodgkin Lymphoma: A Randomized Phase II Study
Francesco Turturro, Luis E Fayad, Anas Younes, Michelle Fanale, Yasuhiro Oki, Hun Ju Lee, Nancy L Bartlett, Haematologica

Abstracts/Posters

Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma _ Cohort Study of 369 Patients
Luis Fayad, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell LymphomaRadiation Therapy Can be ...
Luis Fayad, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clinical Relevance of MYC/BCL2 and Cell of Origin in Patients with Relapsed Diffuse Large B-Cell Lymphoma Treated with Autologous Stem Cell Transplantation
Luis E. Fayad, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Nonmyeloablative Allogeneic Transplantation (NMAT) Confers an Overall Survival Benefit with Similar Non-Relapse Mortality When Compared to Autologous Stem Transplantat...
Luis E. Fayad, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)
Luis Fayad, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma
Luis E. Fayad, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma
Luis Fayad, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell_like (Non-GCB) Diffus...
Luis Fayad, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma
Luis Fayad, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Comparative Review of 30 Day Non-Relapse Mortality (NRM) in B-Cell Lymphomas Associated with Anti-CD19 Chimeric Antigen Receptor T-Cells (CAR-T) from FDA Database, Cli...
Luis E. Fayad, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma...
Luis Fayad, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase II Trial of Nivolumab and Ibrutinib for Patients with Relapsed or Refractory Central Nervous System Lymphoma
Luis Fayad, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R) in Previously Untreated Follicular...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib E...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Prognostic Factors, Outcomes and Clinical Characteristics in Patients with Transformed Follicular Lymphoma (t-FL): Cohort Study of Patients
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

Hodgkin’s Lymphoma Survivor: How My Cancer Journey Led to a Career in Reproductive LawNovember 7th, 2017
Hodgkin’s Lymphoma Survivor: Why I Froze My Eggs Before Cancer TreatmentOctober 17th, 2017